92519-10-3

Basic information

• Product Name: 4(3H)-Pyrimidinone, 2-amino-3-methyl-6-phenyl-
• Synonyms: 2-Amino-3-methyl-6-phenyl-3H-pyrimidin-4-one
• CAS NO: 92519-10-3
• Molecular Formula: C11H11N3O
• Molecular Weight: 201.228
• Mol File: 92519-10-3.mol

Chemical Properties

• Melting Point: 240-240.5 °C(Solv: ethanol (64-17-5); ethyl ether (60-29-7))
• Boiling Point: 369.2±45.0 °C(Predicted)
• Density: 1.24±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 4(3H)-Pyrimidinone, 2-amino-3-methyl-6-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4(3H)-Pyrimidinone, 2-amino-3-methyl-6-phenyl-(92519-10-3)
• EPA Substance Registry System: 4(3H)-Pyrimidinone, 2-amino-3-methyl-6-phenyl-(92519-10-3)

Safety Data

• Hazardous Substances Data: 92519-10-3(Hazardous Substances Data)

Upstream product

• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 1866-88-2 methyl-guanidine; sulfate 
• 56741-94-7 2-amino-6-phenyl-3H-pyrimidin-4-one 
• 74-88-4 methyl iodide 

Downstream Products

• 861840-05-3 3-methyl-2-(2-methylsulfanyl-pyrimidin4-ylamino)-6-phenyl-3H-pyrimidin-4-one 

Relevant articles and documents

SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF

This invention relates to novel compounds having the structural formula Ia or formula Ib: Ia Ib and their pharmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors, compositions and methods of use thereof. These novel compounds provi

SUBSTITUTED AMINO-PYRIMIDONES AND USES THEREOF

This invention relates to novel compounds having the structural formula Ia or formula Ib below: (Ia,Ib), and their phatmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of Abeta related pathologies such as cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to pyrimidinones and pyridones and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic ? cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.